Using metabolomic profiling to screen for endometrial cancer
Official title: Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer
Run by National Cancer Institute, Naples · NCT06893861 · Data updated 2026-11-12
This study is testing a new way to use blood samples to see if certain markers can help identify endometrial cancer in women compared to other types of growths and cancers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | Women only |
| Enrollment | 3100 (estimated) |
| Sponsor | National Cancer Institute, Naples Academic / other |
| Locations | 1 site (Naples) |
| Status | Recruiting |
| Started | July 6, 2023 |
| Main results expected | July 2025 |
| Study ends | July 2025 |
| Registry record updated | March 25, 2025 |
| Trial ID | NCT06893861 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are post-menopausal women aged 50 to 80 who are willing to participate in the study.
✕Probably not a fit
Patients who have undergone a hysterectomy, are on hormone replacement therapy, or are receiving immunosuppressive therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of a metabolomic signature for screening endometrial carcinoma by comparing it against benign endometrial neoplasms and other cancer types. It follows a case-control design, recruiting patients from the IRCCS G. Pascale and Diagnostica Medica for data collection and biological sample analysis. The study aims to assess the discriminative ability of the metabolomic signature through a combination of bioanalytical and bioinformatic methods. Participants will provide blood samples for metabolomic profiling to identify potential diagnostic markers.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate screening for endometrial cancer, improving patient outcomes.
How similar studies have gone: While the use of metabolomic profiling in cancer screening is an emerging field, this specific approach has not been widely tested, making it a novel investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Female sex 2. Age between 50 and 80 years 3. Willingness to participate in the study and signing of the informed consent 4. Clinical condition of post-menopause Exclusion Criteria: 1. Previous hysterectomy 2. Hormone replacement therapy 3. Immunosuppressive therapy
Where it's running
-
Istituto Nazionale Tumori | "Fondazione Pascale"
Naples, Italy Recruiting
Study contacts
- Principal investigator: Antonella De Luca — IRCCS I.N.T. "G. Pascale"
- Study coordinator: Antonella De Luca
- Email: a.deluca@istitutotumori.na.it
- Phone: 08117770603
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prognosis and Therapy Clues in High-Risk, Non-Invasive Endometrial Cancer
This study looks at people with non-invasive endometrial cancer that has high-risk molecular features to see how often lymph nodes are involved and how often the cancer comes back or affects survival after different adjuvant treatments.
-
Short-course CT online-adaptive radiotherapy for post-operative endometrial cancer
This trial tests whether delivering post-operative radiotherapy in 5 sessions using CT online-adaptive radiotherapy is safe and feasible for endometrial cancer patients.
-
GV20-0251 treatment for adults with advanced solid tumors
This study will test GV20-0251 to see if it helps adults with advanced solid tumors that have stopped responding to approved therapies.
-
GV20-0251 treatment for advanced solid tumors
This study is testing a new treatment called GV20-0251 for people with advanced solid tumors that haven't improved with standard treatments, to see how safe it is and if it works better when combined with another medication.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.